🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Jubilant Pharmova Limited JUBLPHARMA NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.jubilantpharmova.com
Company Profile ↓
₹929.40
-13.27% 1Y
Mkt Cap₹14,720.50 Cr
P/E41.92
P/B2.08
Div. Yield0.51%
52W High₹1,175.12
52W Low₹803.49
Book Value₹447.81
EPS (TTM)₹22.17

Company Overview

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of pulmonary embolism, cancer, coronary artery disease, and other diseases. Its Allergy Immunotherapy segment provides specialized diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacture, distribution, sale, and marketing of generic formulations for therapeutic areas, such as cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment provides drug discovery services and active pharmaceutical ingredients. Its Proprietary Novel Drugs segment offers patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organizations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 251.1% per year over the last five years.

Recent Developments

  • Mar 2026 Revenue of ₹8,225.10 Cr (+14.4% YoY); net profit ₹398.50 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +17.3%, earnings -45.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 9.8%, profit CAGR 251.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:9.77%
1 Year:17.30%

Compounded Profit Growth

5 Years:251.09%
1 Year:-45.00%

Stock Price Performance

1 Year:-13.27%
6 Months:-1.18%
3 Months:-3.77%
1 Month:-11.42%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 34% of range
₹803.49 ₹1,175.12
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)36.07 · Neutral
Price Performance
1M-11.42%
3M-3.77%
6M-1.18%
1Y-13.27%
Valuation vs Sector

P/E of 41.92 is above the sector median of 36.43 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 251.1% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
41.92
Industry PE
36.43
Forward P/E
18.39
PEG Ratio
0.14
Book Value
₹447.81
Price to Book
2.08
P/S
1.71
EV/EBITDA
16.07
Dividend Yield
0.51%

Growth (CAGR)

Revenue 5Y
9.77%
Profit 5Y
251.09%
Revenue (YoY)
17.30%
Earnings (YoY)
-45.00%

Profitability & Returns

ROCE
6.28%
ROE
5.62%
ROA
2.57%
Profit Margin
4.09%
Op Margin
5.41%
Gross Margin
64.98%
EPS (Latest Qtr)
₹7.52
EPS (TTM)
₹22.17

Balance Sheet & Liquidity

Debt/Equity
0.51
Quick Ratio
1.13
Current Ratio
1.62
Debt
₹3,614.70 Cr
Total Assets
₹15,522.70 Cr
Current Assets
₹4,109.30 Cr
Working Capital
₹1,570.40 Cr

Ownership

Promoter Holding
56.23%
Chg in Prom Hold
-1.90%
FII / Inst Holding
24.10%
Chg in FII Hold
1.90%

Financial Snapshot

Enterprise Value
₹14,720.50 Cr
Total Revenue (TTM)
₹8,608.30 Cr
EBITDA
₹1,065.27 Cr
Free Cash Flow
₹-222.30 Cr
Operating Cash Flow
₹1,226.80 Cr
Shares Outstanding
₹15.84 Cr
Gross Margin
64.98%
Payout Ratio
22.55%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 JUBLPHARMA Jubilant Pharmova Limited NIFTY_SMALLNSEPHARMA 929.40 41.92 ₹14,720.50 Cr 0.51% 6.28% 5.62% 9.77% 251.09%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 1,678.00 Cr1,587.00 Cr1,680.00 Cr1,677.00 Cr1,759.00 Cr1,732.00 Cr1,752.00 Cr1,813.70 Cr1,915.80 Cr1,878.90 Cr1,966.00 Cr2,116.10 Cr2,272.20 Cr
Cost of Revenue -------574.40 Cr626.10 Cr618.20 Cr-716.30 Cr713.30 Cr
Gross Profit -------1,239.30 Cr1,289.70 Cr1,260.70 Cr-1,399.80 Cr1,558.90 Cr
Operating Expenses 1,459.00 Cr1,419.00 Cr1,438.00 Cr1,459.00 Cr1,487.00 Cr1,480.00 Cr1,463.00 Cr1,043.20 Cr1,039.50 Cr1,069.20 Cr1,625.00 Cr1,231.00 Cr1,336.40 Cr
Operating Income -52.00 Cr78.00 Cr145.00 Cr123.00 Cr170.00 Cr161.00 Cr198.00 Cr196.10 Cr250.20 Cr191.50 Cr236.00 Cr168.80 Cr222.50 Cr
EBITDA 219.00 Cr168.00 Cr242.00 Cr218.00 Cr271.00 Cr252.00 Cr289.00 Cr277.40 Cr353.90 Cr301.50 Cr341.00 Cr270.20 Cr349.30 Cr
Interest Expense 56.00 Cr62.00 Cr66.00 Cr71.00 Cr73.00 Cr71.00 Cr61.00 Cr55.60 Cr52.70 Cr49.00 Cr50.00 Cr56.10 Cr56.50 Cr
Pretax Income -86.00 Cr25.00 Cr98.00 Cr101.00 Cr-54.00 Cr500.00 Cr144.00 Cr130.50 Cr206.00 Cr154.40 Cr190.00 Cr93.40 Cr176.00 Cr
Tax Provision -13.76 Cr19.00 Cr36.26 Cr34.34 Cr-8.10 Cr20.00 Cr41.76 Cr29.80 Cr54.70 Cr51.90 Cr70.30 Cr37.60 Cr56.70 Cr
Net Income -100.00 Cr6.00 Cr62.00 Cr66.00 Cr-62.00 Cr482.00 Cr102.00 Cr100.90 Cr153.60 Cr102.90 Cr120.00 Cr55.90 Cr119.40 Cr
Diluted EPS -6.150.403.924.19-3.6830.266.456.369.686.477.553.527.52

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 5,751.00 Cr5,749.00 Cr5,861.00 Cr7,518.00 Cr9,111.00 Cr5,976.00 Cr6,099.00 Cr-6,219.30 Cr6,644.80 Cr7,192.10 Cr8,225.10 Cr
Cost of Revenue --------2,222.80 Cr2,422.10 Cr2,611.60 Cr2,991.10 Cr
Gross Profit --------3,996.50 Cr4,222.70 Cr4,580.50 Cr5,234.00 Cr
Operating Expenses 5,141.00 Cr4,493.00 Cr4,510.00 Cr5,995.00 Cr7,367.00 Cr4,428.00 Cr4,695.00 Cr-3,766.60 Cr3,699.60 Cr3,773.70 Cr4,414.60 Cr
Operating Income 322.00 Cr909.00 Cr1,061.00 Cr1,107.00 Cr1,373.00 Cr1,208.00 Cr1,054.00 Cr-229.90 Cr523.10 Cr806.80 Cr819.40 Cr
EBITDA 610.00 Cr1,256.00 Cr1,352.00 Cr1,522.00 Cr1,744.00 Cr1,548.00 Cr1,403.00 Cr-750.40 Cr808.80 Cr1,570.10 Cr1,255.90 Cr
Interest Expense 368.00 Cr371.00 Cr341.00 Cr284.00 Cr220.00 Cr200.00 Cr184.00 Cr-168.60 Cr256.40 Cr220.90 Cr201.40 Cr
Pretax Income 40.00 Cr542.00 Cr738.00 Cr859.00 Cr904.00 Cr1,233.00 Cr1,133.00 Cr-27.80 Cr170.50 Cr980.60 Cr614.10 Cr
Tax Provision 80.00 Cr157.18 Cr162.36 Cr223.34 Cr325.44 Cr332.91 Cr294.58 Cr-92.70 Cr97.80 Cr144.30 Cr216.60 Cr
Net Income -40.00 Cr387.00 Cr575.00 Cr634.00 Cr577.00 Cr898.00 Cr836.00 Cr--61.00 Cr77.10 Cr839.40 Cr398.50 Cr
Diluted EPS -3.6324.6036.1440.3536.0656.3952.47--3.834.8652.8525.08

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 8,619.00 Cr8,740.00 Cr8,899.00 Cr9,457.00 Cr11,319.00 Cr12,310.00 Cr8,763.00 Cr-11,156.70 Cr11,548.50 Cr12,756.40 Cr15,522.70 Cr
Current Assets --------3,762.40 Cr3,876.10 Cr3,577.20 Cr4,109.30 Cr
Cash & Equivalents --------1,010.80 Cr953.90 Cr1,086.20 Cr1,265.20 Cr
Inventory --------1,380.50 Cr1,289.60 Cr1,129.20 Cr1,231.50 Cr
Receivables --------961.20 Cr915.90 Cr891.50 Cr1,069.60 Cr
Total Liabilities --------5,764.90 Cr6,127.40 Cr6,517.80 Cr8,427.10 Cr
Current Liabilities --------1,772.40 Cr1,889.00 Cr2,164.60 Cr2,538.90 Cr
Long Term Debt --------3,110.40 Cr3,167.10 Cr2,150.30 Cr2,971.70 Cr
Total Debt 4,793.00 Cr4,493.00 Cr4,045.00 Cr3,469.00 Cr4,840.00 Cr4,808.00 Cr2,830.00 Cr-3,676.80 Cr3,664.00 Cr2,731.00 Cr3,614.70 Cr
Total Equity 2,454.00 Cr2,967.00 Cr3,436.00 Cr4,087.00 Cr4,809.00 Cr5,604.00 Cr4,742.00 Cr-5,399.30 Cr5,433.90 Cr6,254.90 Cr7,092.80 Cr
Shares Outstanding --------15.93 Cr15.93 Cr15.93 Cr15.93 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 783.00 Cr1,099.00 Cr1,268.00 Cr1,303.00 Cr1,122.00 Cr1,543.00 Cr1,784.00 Cr-660.70 Cr971.30 Cr1,072.10 Cr1,226.80 Cr
Investing Cash Flow -362.00 Cr-309.00 Cr-465.00 Cr-614.00 Cr-1,018.00 Cr-267.00 Cr-727.00 Cr--544.40 Cr-607.90 Cr487.70 Cr-1,260.00 Cr
Financing Cash Flow -503.00 Cr-843.00 Cr-686.00 Cr-901.00 Cr657.00 Cr-1,050.00 Cr-1,709.00 Cr--156.70 Cr-432.50 Cr-1,452.70 Cr94.90 Cr
Capital Expenditure -349.00 Cr-339.00 Cr-462.00 Cr-484.00 Cr-649.00 Cr-568.00 Cr-514.00 Cr--814.50 Cr-897.70 Cr-1,115.60 Cr-1,449.10 Cr
Free Cash Flow 434.00 Cr760.00 Cr806.00 Cr819.00 Cr473.00 Cr975.00 Cr1,270.00 Cr--153.80 Cr73.60 Cr-43.50 Cr-222.30 Cr
Net Change in Cash -82.00 Cr-52.00 Cr117.00 Cr-212.00 Cr761.00 Cr225.00 Cr-652.00 Cr--40.40 Cr-69.10 Cr107.10 Cr61.70 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------64.3%63.5%63.7%63.6%
Operating Margin % 5.6%15.8%18.1%14.7%15.1%20.2%17.3%-3.7%7.9%11.2%10.0%
Net Margin % -0.7%6.7%9.8%8.4%6.3%15.0%13.7%--1.0%1.2%11.7%4.8%
ROE % -1.6%13.0%16.7%15.5%12.0%16.0%17.6%--1.1%1.4%13.4%5.6%
ROCE % --------2.4%5.4%7.6%6.3%

Shareholding Pattern

Insiders
56.23%
Institutions
24.10%
Public Float
55.06%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JUBLPHARMA

Google News Fri, 16 Oct 2026

Jubilant Pharmova Limited: Financial Data Forecasts Estimates and Expectations | JUBLPHARMA | INE700A01033 - www.marketscreener.com

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUlpwUU1WMldwLUJ5cmF2akhNNndZSFVQNk5kalloUnNZRTJ6MWJZQ0tRV2ZrSVhldFNjSU9HNjdLdTBSa0pCT0ZLYXlvSjkxT2pwS0lZQmxKSkJtaE5Yc05xdlFSMGVqNzZ1MzZQckpCWWNWbjRXa0RqU2VGUGhPdWt0TVBEdkFna1hwc2…

Google News hu, 25 Jun 2026

JUBLPHARMA Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTFBCcnRZamZhZW5FOFRhOWw5Z092NzQ4dzVzdnlzNXRyWmN4bExGRk1Vc3lvaXByMXB3UmpLUlpkZnczMHV5ZFZ4aFVBQ1I3WFY2cnZXQnZwWU1sSFVZdC1zYkUzNElZemFiS2NiT1pqTVpyeFNpd3lncExYWk1iZw?oc=5" target="_blan…

Google News ue, 13 Oct 2026

Jubilant Pharmova (JUBLPHARMA) Share Price Today, Live Chart, News - TechGraph

<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTFAyclBLemFCanVwdGZnVmtTZHVQOFdzX2RfMmh6U3VVNTBRUDFDOWUzT0hSNEQxc1dVLWdQTmdiSlR2UGJGNURNSFBsVXRDN2kzTnd3NFczY1FTaGhxaTVic215eWo?oc=5" target="_blank">Jubilant Pharmova (JUBLPHARMA) S…

Google News ue, 13 Oct 2026

Quant MF Sells ₹100 Cr Stake in Jubilant Pharmova - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdVJwSG9uWV8ycTlIMjJVNDRxU08xNXg3dWR4TXFtdVBCYVRYSXFhTTN6VzRsSmI5QVFzU2dVMGFna2prNHB1ZVVscm1Od3Bhd1hsN2hDX3hQRVpoOTNDZHc5TWQ2blY0MnlXRklzYnhBZ29yV3EzTkFCbHJDMDAxeG1USEotemw4VWYxLV…

Google News ue, 13 Oct 2026

Quant MF sells Jubilant Pharmova stake for over ₹100 crore; stock falls over 2% - TradingView

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQb3ZMVUJLaXpNcmJkN0xNdEUyemxQbl8zUlZqbWdPb0IxQW5IQXM5dEpveUY0R2VsSVAtaldXdVphSjVrVTVHc1NOeloxUTNfd0k5bW5DY1BCWEJaVlZOQmxTTjJCTWFYSGt5WVhIUDZVMWNhRVJBTXNfT2c3dVg4S0J6SjNSTmJ4TklUVj…

Google News Fri, 18 Sep 2026

Jubilant Pharmova Share Price update: fundamentals and peers - Univest

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNTGlibHRIcDhmSXRsek0xRFpvbi1ta1RvYkFpcEN1aGljdC1SU1NfckdURnFHUm1tOVNiVjhhYldteUVXWUhwUEV3YlVFaGdzUmQtbWFjV21QTElSX096ZmYtZmxVVWQ4RVBDcmlCUE0tLXVYWjR1RThIZ2RweE85OXI0M0RQSmg0WTNQOA…

JUBLPHARMA — Frequently Asked Questions

What is the current share price of Jubilant Pharmova Limited (JUBLPHARMA)?

As of 2026-10-23 04:58 IST, Jubilant Pharmova Limited (JUBLPHARMA) trades at ₹929.40 on NSE. Its 52-week range is ₹803.49 to ₹1,175.12.

What is the market capitalisation of JUBLPHARMA?

Jubilant Pharmova Limited (JUBLPHARMA) has a market capitalisation of ₹14,720.50 Cr on NSE.

What is the P/E ratio of JUBLPHARMA?

JUBLPHARMA trades at a trailing price-to-earnings (P/E) ratio of 41.92. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 2.08.

Does JUBLPHARMA pay a dividend?

Jubilant Pharmova Limited (JUBLPHARMA) currently offers a dividend yield of 0.51%.

What is the return on equity (ROE) of JUBLPHARMA?

JUBLPHARMA has a return on equity (ROE) of 5.62%. Its return on capital employed (ROCE) is 6.28%.

Is JUBLPHARMA a good stock to buy?

This page provides a data-driven analysis of Jubilant Pharmova Limited (JUBLPHARMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space